QUICKly Eradicate Hepatitis C in Patients Undergoing REnal Transplant With 4 Weeks of Glecaprevir/Pibrentasvir

Part of paid clinical trials in Boston, Massachusetts.

Sponsor
Massachusetts General Hospital
Study ID
NCT04515797
Phase
PHASE4
Status
Terminated

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Glecaprevir and Pibrentasvir — DRUG
    4 weeks of treatment starting within 24 hrs of kidney transplant

Study Details

This is a single center study characterizing the experience of administration of 4 weeks of pan-genotypic DAA therapy in kidney transplantation to prevent the transmission of hepatitis C virus infection from an HCV-positive donor kidney to an HCV-negative recipient.

Key Dates

Start date
May 1, 2021
Status verified
Nov 2024
Primary completion
Aug 31, 2023
Completion
Aug 31, 2023

Study Design

Enrollment
2 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Treatment with Direct Acting Antiviral for HCV
    4 week treatment period with glecaprevir and pibrentasvir (G/P) within 24 hours of transplant

Primary Outcome Measure

Number of Participants With Undetectable Blood HCV RNA Level [ Time Frame: 12 weeks post last dose of treatment with G/P ]

Locations (1)

FacilityCityStateZIPSite coordinators
Massachusetts General HospitalBostonMassachusetts02114-

Find similar trials in Boston, MA

By research site
Massachusetts General Hospital· Boston, MA

Related Studies